Evidence map›Paper›PMID 39532981›Full record

ArticleScientific reports2024

Major alteration of lung microbiome and the host responses in critically ill COVID-19 patients with high viral load.

Ingrid G Bustos, Rosana Wiscovitch-Russo, Harinder Singh, Benjamín L Sievers, Michele Matsuoka, Marcelo Freire, Gene S Tan, Mónica P Cala, Jose L Guerrero, Ignacio Martin-Loeches and 2 more

Abstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Palmitoleic acid loss links pulmonary dysbiosis to lung injury after single-lung ventilation.American journal of respiratory cell and molecular biology · 2026
    Article
  4. Article
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Ingrid G Bustos *Unisabana Center of Translational Science, Universidad de La Sabana, Campus Puente del Común, KM 7.5 Autopista Norte de Bogotá, Chia, Colombia.
Rosana Wiscovitch-Russo *Infectious Diseases and Genomic Medicine Group, J Craig Venter Institute, 9605 Medical Center Drive Suite 150, Rockville, MD, 20850, USA.
Harinder Singh *Infectious Diseases and Genomic Medicine Group, J Craig Venter Institute, 9605 Medical Center Drive Suite 150, Rockville, MD, 20850, USA.
Benjamín L SieversInfectious Disease Group, J Craig Venter Institute, 4120 Capricorn Ln, La Jolla, CA, USA.
Michele MatsuokaInfectious Disease Group, J Craig Venter Institute, 4120 Capricorn Ln, La Jolla, CA, USA.
Marcelo FreireInfectious Disease Group, J Craig Venter Institute, 4120 Capricorn Ln, La Jolla, CA, USA.
Gene S TanInfectious Disease Group, J Craig Venter Institute, 4120 Capricorn Ln, La Jolla, CA, USA.
Mónica P CalaMetCore-Metabolomics Core Facility, Vice-Presidency of Research and Knowledge Creation, Universidad de Los Andes, Bogotá, Colombia.
Jose L GuerreroMetCore-Metabolomics Core Facility, Vice-Presidency of Research and Knowledge Creation, Universidad de Los Andes, Bogotá, Colombia.
Ignacio Martin-LoechesMultidisciplinary Intensive Care Research Organization (MICRO), St James's Hospital, Dublin, Ireland.
Norberto Gonzalez-Juarbe *Infectious Diseases and Genomic Medicine Group, J Craig Venter Institute, 9605 Medical Center Drive Suite 150, Rockville, MD, 20850, USA. ngonzale@jcvi.org.
Luis Felipe Reyes *Unisabana Center of Translational Science, Universidad de La Sabana, Campus Puente del Común, KM 7.5 Autopista Norte de Bogotá, Chia, Colombia. luis.reyes5@unisabana.edu.co.

Funding

Endolysins as tools to eradicate pneumococcal biofilms and development ofprotective immunityR01AI168313 · NIAID · UNIV OF MARYLAND, COLLEGE PARK · PI Norberto Gonzalez-Juarbe · 2023 to 2026
$3.5M
Development of novel protein-based vaccine formulations to prevent pneumococcal colonization and diseaseR21AI148722 · NIAID · J. CRAIG VENTER INSTITUTE, INC. · PI GONZALEZ-JUARBE, NORBERTO · 2020 to 2021
$542k
Conrad Prebys Foundation 204National Institute of Allergy and Infectious Diseases AI168313National Institutes for Health R01AI168313NIAID NIH HHS R01 AI168313NIAID NIH HHS R21 AI148722NIH HHS R21AI148722Universidad de La Sabana MED-289-2020
6 · The paper itself

Abstract

Patients with COVID-19 under invasive mechanical ventilation are at higher risk of developing ventilator-associated pneumonia (VAP), associated with increased healthcare costs, and unfavorable prognosis. The underlying mechanisms of this phenomenon have not been thoroughly dissected. Therefore, this study attempted to bridge this gap by performing a lung microbiota analysis and evaluating the host immune responses that could drive the development of VAP. In this prospective cohort study, mechanically ventilated patients with confirmed SARS-CoV-2 infection were enrolled. Nasal swabs (NS), endotracheal aspirates (ETA), and blood samples were collected initially within 12 h of intubation and again at 72 h post-intubation. Plasma samples underwent cytokine and metabolomic analyses, while NS and ETA samples were sequenced for lung microbiome examination. The cohort was categorized based on the development of VAP. Data analysis was conducted using RStudio version 4.3.1. In a study of 36 COVID-19 patients on mechanical ventilation, significant differences were found in the nasal and pulmonary microbiome, notably in Staphylococcus and Enterobacteriaceae, linked to VAP. Patients with VAP showed a higher SARS-CoV-2 viral load in respiratory samples, elevated neutralizing antibodies, and reduced inflammatory cytokines, including IFN-δ, IL-1β, IL-12p70, IL-18, IL-6, TNF-α, and CCL4. Metabolomic analysis revealed changes in 22 metabolites in non-VAP patients and 27 in VAP patients, highlighting D-Maltose-Lactose, Histidinyl-Glycine, and various phosphatidylcholines, indicating a metabolic predisposition to VAP. This study reveals a critical link between respiratory microbiome alterations and ventilator-associated pneumonia in COVID-19 patients with higher SARS-CoV-2 viral loads in respiratory samples, elevated neutralizing antibodies, and reduced inflammatory cytokines, including IFN-δ, IL-1β, IL-12p70, IL-18, IL-6, TNF-α, and CCL4. These findings provide novel insights into the underlying mechanisms of VAP, with potential implications for management and prevention.

Indexed as

COVID-19Critical IllnessCytokinesLungMicrobiotaPneumonia, Ventilator-AssociatedRespiration, ArtificialSARS-CoV-2Viral LoadAgedFemaleHumansMaleMiddle AgedProspective StudiesCytokinesCOVID-19CytokinesMechanical ventilationMetabolomeMicrobiotaMicrobiota-virus-disease interactions

Identifiers

PMID39532981
PMCPMC11557576

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.